![Barry Gallagher](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Barry Gallagher served as the Chief Executive Officer at Drive from 1992 to 2018.
Former positions of Barry Gallagher
Companies | Position | End |
---|---|---|
Drive
![]() Drive Miscellaneous Commercial ServicesCommercial Services Drive is a non-profit LLC that focuses on discovering and developing antiviral drugs for emerging infections, pandemic threats, and biodefense. The non-profit company is based in Nantgarw, UK. The British company operates like an early stage biotechnology company and applies focus and industry development expertise to efficiently translate discoveries to address viruses of concern. The company is unique in that it brings industry expertise to the assets of a leading research university to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. The company was founded in 1983. Rhian Jones has been the CEO of the company since 2018. | Chief Executive Officer | 2018-09-17 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Drive
![]() Drive Miscellaneous Commercial ServicesCommercial Services Drive is a non-profit LLC that focuses on discovering and developing antiviral drugs for emerging infections, pandemic threats, and biodefense. The non-profit company is based in Nantgarw, UK. The British company operates like an early stage biotechnology company and applies focus and industry development expertise to efficiently translate discoveries to address viruses of concern. The company is unique in that it brings industry expertise to the assets of a leading research university to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. The company was founded in 1983. Rhian Jones has been the CEO of the company since 2018. | Commercial Services |
- Stock Market
- Insiders
- Barry Gallagher